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Abstract
Background: Michiels et al. (Lancet 2005; 365: 488–92) employed a resampling strategy to show
that the genes identified as predictors of prognosis from resamplings of a single gene expression
dataset are highly variable. The genes most frequently identified in the separate resamplings were
put forward as a 'gold standard'. On a higher level, breast cancer datasets collected by different
institutions can be considered as resamplings from the underlying breast cancer population. The
limited overlap between published prognostic signatures confirms the trend of signature instability
identified by the resampling strategy. Six breast cancer datasets, totaling 947 samples, all measured
on the Affymetrix platform, are currently available. This provides a unique opportunity to employ
a substantial dataset to investigate the effects of pooling datasets on classifier accuracy, signature
stability and enrichment of functional categories.
Results: We show that the resampling strategy produces a suboptimal ranking of genes, which can
not be considered to be a 'gold standard'. When pooling breast cancer datasets, we observed a
synergetic effect on the classification performance in 73% of the cases. We also observe a significant
positive correlation between the number of datasets that is pooled, the validation performance, the
number of genes selected, and the enrichment of specific functional categories. In addition, we have
evaluated the support for five explanations that have been postulated for the limited overlap of
signatures.
Conclusion: The limited overlap of current signature genes can be attributed to small sample size.
Pooling datasets results in more accurate classification and a convergence of signature genes. We
therefore advocate the analysis of new data within the context of a compendium, rather than
analysis in isolation.
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Background
Various gene expression signatures have been extracted
from breast cancer microarray data [1,2] to predict out-
come. Subsequently, these signatures have been validated
in larger cohorts [3,4], the datasets were re-analyzed to
assess their robustness [5], or other data mining tech-
niques were tested [6,7]. Depending on the technique
used, different signatures are extracted from the same
dataset. Often, these signatures have varying degrees of
overlap in genes that compose the signature [8]. This has
led to the insight that there is no unique signature [9].
From a clinical point of view, accuracy of a signature is
very important [10]. To extract such an accurate gene
expression signature, which is predictive of outcome, a
variety of methodologies have been proposed [11,12].
Typically, the group of patients is dichotomized based on
a five year survival threshold, resulting in a poor and a
good outcome group. This assignment then serves as a
class label, and the aim of this work is to predict this label.
Most protocols apply a cross validation scheme, with
which the generalization error and optimal number of
genes are estimated. A final classifier is obtained by select-
ing the optimal number of genes and training the final
classifier on all samples.
Michiels et al. [5] introduced the concept of repeated ran-
dom resampling to estimate the robustness (stability) of
proposed signatures. The strategy relies on repeatedly ana-
lyzing a subset of patients in a dataset (a resampling), and
then combining the results of the separate resamplings
into a final list of genes. This strategy has been employed
to investigate the stability of proposed signatures, and
produces, by repeated resampling, a gene list which is
employed as a type of 'gold standard'. This 'gold standard'
has been shown to be different from signatures previously
reported on the same data [5,13,14].
However, the repeated random resampling approach has
several drawbacks. First, resampling selects a subset of the
available data, thereby reducing the number of samples
and intensifying the small sample size problem. Second,
the actual ranks within each resampling are not used
(only presence in the top N genes is employed as a quality
measure), which implies that the available information is
not fully exploited. Lastly, the true rank of genes is
unknown, making it hard to show that this strategy
indeed provides a better ranking.
We set up an experiment using artificial datasets to test the
resampling strategy in a controlled environment. This
allowed us to compare the resampling based ranking to
the true ranking. In this comparison, we included two var-
iants of the resampling strategy, and a non-resampling
based strategy. On a higher level, datasets from different
institutions consisting of samples from the same disease
type, can be viewed as resamplings from the same under-
lying population. Concurrent analysis of these datasets
aimed at, for example, producing a classifier, can be per-
formed using a range of integration strategies. From a sta-
tistical point of view, a larger dataset implies more
statistical power, advocating an early integration
approach where (normalized) datasets are pooled prior to
the analysis [6]. A classifier derived from such a pooled
dataset, should, in theory, be superior to those derived
from a single dataset. Of course, in order to minimize
inter-dataset variability, one of a variety of normalization
techniques should be employed (e.g. Z-score normaliza-
tion per feature per dataset) prior to pooling the datasets.
Alternatively, a rank-based classification methodology
has been put forward [15,16], which is independent of
dataset normalization. Moreover, heterogeneity in the dif-
ferent datasets might be a hurdle [17], which might not be
overcome with simple normalization approaches. In such
cases, performing a meta-analysis may be advantageous,
which implies combining statistics from each dataset.
Lastly, 'late integration' (also termed 'combining deci-
sions') involves training a classifier on the separate data-
sets and then merging the separate decisions to reach a
final result. In fact, this approach possesses the least statis-
tical power, since each of the individual classifiers have no
benefit from the other datasets.
A setting using artificial datasets, allows for a controlled
analysis of the effects observed when pooling these artifi-
cial datasets. If synergy exists between the artificial data-
sets, we hypothesize that the classifier performance
should improve when more artificial datasets are pooled.
Therefore, we extended our analysis on artificial data to
multiple artificial datasets. First of all, we start pooling
pairs of artificial datasets, and thereafter increase the
number of pooled datasets pooled until all six artificial
datasets are pooled. We explored the effect of pooling arti-
ficial datasets on the classification performance (double
loop cross validation), independent validation, and signa-
ture size.
Currently, multiple breast cancer datasets are publicly
available [1,2,18,19]. Teschendorff et al. [20] created a
consensus ER positive classifier from three breast cancer
datasets employing a meta-analysis strategy.
These datasets were measured on different platforms,
thereby introducing difficulties with respect to probe
matching, and the fact that different reference pools may
have been used. If direct pooling of the datasets would be
allowed, such a meta-analysis would not yield the optimal
result. Moreover, true synergy of the meta-analysis on
multiple datasets wasn't shown. Similarly, Xu et al. [21]
have created a consensus rank-based classifier from threeBMC Genomics 2008, 9:375 http://www.biomedcentral.com/1471-2164/9/375
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different datasets, which was validated on a fourth inde-
pendent dataset. To validate the type of effects observed
when pooling artificial datasets, we applied the same
analysis to a compendium of six breast cancer datasets
(Desmedt et al. [4], Minn et al. [22], Miller et al. [18], Paw-
itan et al. [23], Loi et al. [24], Chin et al. [25]). This com-
pendium of breast cancer datasets is particularly suited for
such an analysis, since they were all measured on the same
platform (Affymetrix HG U133A). In this setup, we
inspected the effect of pooling breast cancer datasets on
the classification performance (double loop cross valida-
tion), independent validation (a seventh dataset), signa-
ture size, and functional enrichment.
Lastly, the analysis on such a compendium of six breast
cancer datasets, might provide answers to an important
unsolved question: why is there only limited overlap
between existing signatures? [8] As potential explana-
tions, several explanations have been postulated, none of
which have up to now been rigorously tested. We employ
the results obtained when progressively pooling more
breast cancer datasets, to provide insight into the correct-
ness of the five explanations, and identify sample size as
the most likely cause of limited signature overlap.
Results and discussion
Resampling on a single breast cancer dataset
We applied the repeated random resampling strategy (see
Methods section) on the Veer et al. [1] dataset, see Figure
1. When comparing the frequency-based ranking to the
set of genes in the published 70-gene and 231-gene signa-
tures, there appear to be additional genes with high fre-
quencies of occurrence that were not part of the published
signatures. Both Michiels et al. [5], and Roepman et al.
[13] point out that the genes with high frequencies of
occurrence, which are not part of the original signature,
are of high interest. They hypothesize that these genes
were probably not picked up in the signatures due to sam-
pling specific biases in the dataset. This suggests a benefi-
cial effect due to the resampling which does pick them up.
However, since the true ranking of genes underlying
breast cancer outcome is unknown, a plausible alternative
hypothesis could be that those genes are false positives.
Roepman et al. [13] considers all genes with a non-zero
frequency of occurrence to represent a robust signature.
This seems rather optimistic, since genes will be expected
to have a positive frequency by chance. Therefore, we pro-
pose to set a threshold to prune the set of genes to only
those with a frequency higher than expected by chance
(see Methods section). This threshold is indicated by the
vertical red line in Figure 1. The set of genes retained after
this pruning step still contains all genes from the original
signatures, i.e. all light-blue bars (the original signatures)
reside on the left of the threshold. Of course, the ranking
itself remains unchanged.
In the current experimental setting, it is impossible to con-
clude which hypothesis correctly describes the appearance
of genes with a high (above the threshold) frequency of
occurrence, that were not in the original signature.
Resampling on a single artificial dataset
We set up an experiment on artificial data to be able to
compare the ranking after resampling to a known ground
truth (see Methods section). The artificial dataset mimics
a microarray dataset, and consists of 5000 genes, of which
either 500, 2500 or 5000 genes were informative. The
Result of the repeated random resampling procedure on the Veer et al. [1] data Figure 1
Result of the repeated random resampling procedure on the Veer et al.[1] data. The histogram shows the frequen-
cies of genes being among the top 200 genes over 500 resamplings. Below the histogram, two lanes containing light-blue bars 
indicate the genes that are part of the published signatures. The red line indicates the frequency threshold corresponding to 
the expected value of the frequency under the null hypothesis (no information) given the number of genes N that is selected in 
each of the R resamplings.
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experiments were done using artificial datasets consisting
of 100 to 1000 samples, with equal priors for the two
classes. The data was sampled from a class-conditional
gaussian distribution, without any covariance structure.
Since genes are assumed to be independent, these datasets
are more ideal than real microarray datasets. Nevertheless,
this controlled, artificial setting can be a useful tool to
gain insight into the relationship between sample size and
gene selection.
On these artificial datasets we compare the ranking result-
ing from the resampling strategy with the ranking based
on all samples. Additionally, we also consider two vari-
ants of the resampling strategy. Instead of only storing the
top N genes in each of the resamplings, we sum the statis-
tics (sum of ranks or sum of signal-to-noise ratios (SNRs))
of the genes across all the resamplings, and base the final
ranking on this cumulative statistic. Summing the statis-
tics amounts to a 'meta-analysis', and the Top N method
is a 'combining decisions' approach. We then compare the
ranking obtained by each method to the ground truth
(Spearman rank correlation). Since a particular initializa-
tion of the artificial data might influence the results, we
repeated the entire experiment 100 times, and present sta-
tistics across all repeats (average and standard deviation).
Figure 2 shows the Spearman rank correlation between
the known ranks of the artificial data and those obtained
by the Top N resampling approaches, the two resampling
variants, and the ranking over all samples. For N we con-
sidered values of 50, 100 and 200, similar to Michiels et
al. [5], and Roepman et al. [13].
Spearman rank correlation of the ranking obtained after resampling an artificial dataset and the true ranking Figure 2
Spearman rank correlation of the ranking obtained after resampling an artificial dataset and the true ranking. 
The number of informative genes was varied from 500 (A and D), 2500 (B and E), to 5000 (C and F), and 100 (A, B and C) or 
500 (D, E and F) resamplings were considered. The errorbars indicate the mean and standard deviation over 100 repeats of the 
entire experiment. The results from the 'All Samples', 'Sum of Ranks', and 'Sum of SNRs' methods are equivalent, and are 
therefore plotted on top of each other (top line in all plots).
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Figure 2 indicates that the ranking based on all samples
outperforms the ranking obtained from resampling and
then determining the frequency of being in the top N. Fur-
thermore, it is evident that combining the statistics (sum
of ranks or sum of SNRs) of each resampling performs
similar to the ranking over all samples. In fact, it is quite
straight-forward to show analytically that, for a given
gene, the summation of SNRs across resamplings is equal
to the SNR over all samples (see Additional file 1). This is
true when enough resamplings are performed, and they
are uniformly sampled from the complete dataset.
For smaller artificial datasets the obtained Spearman rank
correlations are lower compared to larger artificial data-
sets. The reduced sample size is the most plausible expla-
nation for this effect. For larger artificial datasets, the gap
in performance between the top N resampling approaches
and the sum of ranks and sum of SNRs widens, indicating
that the latter two methods profit more from an increase
in artificial dataset size.
Taken together, these results clearly show that the random
resampling strategy produces a suboptimal ranking of the
prognostic genes, and that it is preferable to employ a
ranking based on all samples in the dataset. In addition,
these differences become more pronounced as the sample
size increases. Given that these effects are already evident
on an artificial dataset, we hypothesize that the sample
size effects will be even stronger on data with a complex
covariance structure. We therefore conclude that it is
unwise to use the repeated random resampling approach
on real data for ranking features.
Pooling artificial datasets
The experiment on a single artificial dataset is easily
extendible to a scenario where multiple artificial datasets
are available. Such a setup would emulate the availability
of several microarray datasets from the same biological
context. We hypothesize that a significant association
exists between the classification error and the number of
datasets pooled.
We set up an experiment using six artificial datasets, each
with 200 samples and 5000 genes, of which 500 are
informative. Each of these six artificial datasets were gen-
erated using the same model, and no additional noise or
heterogeneity was introduced. This represents the ideal
case, where each of the six datasets are truly relevant for
the same underlying problem. We applied the double
loop cross validation (DLCV, nearest mean classifier) pro-
tocol on each artificial dataset separately (see Methods
section), and each possible pooled subset of artificial
datasets. First of all, we inspected the behavior of pooling
pairs of artificial datasets relative to the performance on
the individual artificial datasets. A DLCV error which is
lower for the pooled pair compared to the individual
errors implies a synergetic effect on the classification per-
formance. When the pooled DLCV error is between the
two individual errors, and lower/higher than the weighted
mean (number of samples chosen as weights) we label the
effect as marginal synergetic/marginal anti-synergetic.
Conversely, if the DLCV error is strictly higher than the
individual errors it is labeled as anti-synergetic. Figure 3
shows a network indicating the type of synergy that was
observed for the six artificial datasets, labeled Art1 to Art6.
Figure 3 shows that there is a synergetic effect on the
DLCV error for 14 of the 15 pooled pairs of artificial data-
sets. A marginal anti-synergetic effect is only observed in
one of the 15 cases. This suggests a large gain in statistical
power when pooling the artificial datasets.
Next, we evaluated the DLCV error for every potential
pooling of one to six artificial datasets. In addition, we
evaluated the performance of each of the classifiers
derived from the pooled data on an independent large val-
idation set of 2000 artificial samples, see Figure 4A and
4B. Figure 4A and 4B show that a high degree of synergy is
obtained by pooling artificial datasets. Both the DLCV
error as well as the error on the validation set show a
highly significant correlation with the number of artificial
datasets that is pooled, Pearson correlation of -0.91 (p =
1.1e - 24) and -0.95 (p = 1.4e - 31), respectively.
To test whether the observed trends are classifier specific,
we repeated the experiment using non-linear classifiers (as
opposed to the linear nearest mean classifier used above).
Thus, we repeated the experiment using a K-Nearest
Neighbor classifier (K-NN) as well as a Support Vector
Machine with a Radial Basis Function as kernel (SVM with
RBF kernel). Using these classifiers, we observed the same
trends for the DLCV and Validation error. That is, in all
cases the performance gets better after pooling the artifi-
cial datasets (trends significant, p < 0.05). However, the
errors obtained are higher than those from the NMC. The
plots are shown in Additional files 2 and 3.
In addition to the classification performance, we looked
at the optimal number of genes that is selected by the clas-
sifiers, see Figure 4C. It turns out that there is a highly sig-
nificant positive trend (Pearson correlation 0.85, p = 1.8e
- 18) towards selecting more genes when artificial datasets
are pooled.
In summary, pooling artificial datasets shows that larger
training sets result in larger gene sets being selected and,
most importantly, in better classification performance.
Since this effect is already clearly present in the simple
model, we believe that this effect will be even stronger in
more complex models which include, for example, a cov-BMC Genomics 2008, 9:375 http://www.biomedcentral.com/1471-2164/9/375
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ariance structure between genes. This stems from the fact
that these more complex models will require more data
(relative to the simple models) to accurately estimate the
required complex classifiers.
Pooling breast cancer datasets
We used a compendium of six Affymetrix breast cancer
datasets to evaluate the effect of pooling datasets on the
performance of classifiers (see Table 1 and methods sec-
tion). Our aim is to classify patients into the poor/good
outcome groups as well as possible. To this end, we fol-
lowed the same strategy as on the artificial datasets. First,
we inspected the synergy effect on the DLCV error
achieved on pairs of datasets relative to the DLCV errors
on the individual datasets (DLCV, nearest mean classi-
fier). Figure 5 shows a network indicating the synergy
among the six real datasets.
Figure 5 shows that for 11 of the 15 pairwise pooled data-
sets a synergetic effect was observed (green/blue link). For
4 of the 15 pairwise pooled datasets there was a marginal
anti-synergetic effect (yellow link), and for none of the
pairs the effect was anti-synergetic (orange link).
As a next step we applied the DLCV framework on each
potential pooling of the datasets, and assessed the DLCV
error. In addition, we evaluated the performance of each
classifier on a seventh independent dataset (Vijver et al.
[3]). Figure 6A and 6B show the DLCV error and valida-
tion error as a function of the number of datasets pooled.
There is a clear trend indicating that the DLCV error
decreases when more datasets are pooled (see Figure 6A).
The observed trend has a Pearson correlation of -0.26,
which is significant: p = 4.0e - 2. Of course, since the dif-
ferent datasets have different numbers of samples, an
alternative would be to evaluate the correlation of the
error and the actual number of samples in the pooled
datasets. Doing this unveils a similar significant correla-
tion (Additional file 4).
The results on the seventh independent validation set
(Vijver  et al. [3] data) confirm the synergetic effect
obtained by pooling datasets (see Figure 6B). The trend is
even more pronounced at a Pearson correlation of -0.35,
with p = 5.0e - 3. In addition, in a multivariate Cox pro-
portional hazards model the signature is an independent
Network indicating the synergy between six artificial datasets (Art1 to Art6) Figure 3
Network indicating the synergy between six artificial datasets (Art1 to Art6). Each of these six datasets were gen-
erated from the same model, without introducing any noise or heterogeneity. Each node represents a dataset, and each edge 
the effect on the DLCV error when pooling them. Four different effects were considered, synergy (bright green) when the 
pooled error is lower than each of the separate errors. Marginal synergy (light blue) when the pooled error is lower than the 
weighted mean of the separate errors, conversely marginal anti-synergy (yellow) when it is higher. Lastly, true anti-synergy 
(orange) indicates a higher DLCV error for the pooled dataset.
Art1
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Art5 Art6
Synergy
Marignal Synergy
Marginal Anti−Synergy
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predictor of outcome in the presence of the standard clin-
ico-pathological variables (data not shown). Similarly,
plotting the results in a Kaplan-Meier plot indicates a
highly significant separation (p = 9.5e - 7, logrank test,
data not shown).
The nearest mean classifier that was used in the above
experiment is a relatively simple linear classifier, which is
known to perform well on this type of data [26]. To test
whether the observed trend is classifier specific, we
repeated the experiment using non-linear classifiers. Thus,
Scatterplot indicating the classification error relative to the number of datasets that is pooled Figure 4
Scatterplot indicating the classification error relative to the number of datasets that is pooled. A) DLCV error. 
B) Error on a large independent validation set of 2000 samples. C) Number of genes selected by the DLCV protocol. The color 
corresponds to the number of datasets that was used. Poolings with the same number of datasets are sorted based on error/
number of genes. Labels indicate which combination of datasets was used.
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Correlation between the number of datasets pooled and DLCV error: Pearson=−0.91 p=1.07e−024
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Correlation between the number of datasets pooled and validation error: Pearson=−0.95 p=1.41e−031
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we repeated the experiment using a K-Nearest Neighbor
classifier (K-NN) as well as a Support Vector Machine with
a Radial Basis Function as kernel (SVM with RBF kernel).
The results that were obtained for the DLCV error and the
validation error on the Vijver dataset are shown in Addi-
tional files 5 and 6, for the K-NN and SVM classifiers,
respectively.
Overall, the average eFPFN across all 63 different pooling
combinations when using the K-NN classifier (DLCV =
0.356) is slightly worse compared to the nearest mean
classifier (DLCV = 0.348). In addition, the error obtained
using the SVM (DLCV = 0.391) is higher than the K-NN.
Similarly, the average error on the independent validation
set (Vijver) is also higher: (0.329 for the NMC, 0.365 for
the K-NN and 0.405 for the SVM). This corresponds to the
previous observation that simpler classifier often perform
better on this type of data. At the same time, the trend that
classifiers that are derived from pooled datasets are more
accurate is also observed.
Table 1: Indication of the origin of the seven datasets that were used.
All ER ER pos ER neg
Publication: Label Survival Total Poor Good Poor Good Poor Good
Desmedt et al. [4] Des (D) DMFS 120 29 91 16 65 13 26
Minn et al. [22] Min (Mn) DMFS 62 21 41 9 30 12 11
Miller et al. [18] Mil (Ml) SOS 193 37 156 26 117 11 39
Pawitan et al. [23] Paw (P) SOS 142 22 120 14 99 8 21
Loi et al. [24] Loi (L) DMFS 120 28 92 21 71 7 21
Chin et al. [25] Chi (C) DMFS 86 23 63 14 50 9 13
Vijver et al. [3] Vij (V) DMFS 248 70 178 44 149 26 29
The Survival column indicates the type of survival data that was used; DMFS Distant Metastasis Free Survival; SOS breast cancer Specific Overall 
Survival. Lastly, for each dataset the total number of samples is indicated along with the number of poor/good samples per ER subgroup.
Network indicating the synergy between six real datasets Figure 5
Network indicating the synergy between six real datasets. Each node represents a dataset, and each edge the effect on 
the DLCV error when pooling them. Four different effects were considered, synergy (bright green) when the pooled error is 
lower than each of the separate errors. Marginal synergy (light blue) when the pooled error is lower than the weighted mean 
of the separate errors, conversely marginal anti-synergy (yellow) when it is higher. Lastly, true anti-synergy (orange) indicates a 
higher DLCV error for the pooled dataset.
Des
Min Mil
Paw
Loi Chi
Synergy
Marignal Synergy
Marginal Anti−Synergy
Anti−SynergyBMC Genomics 2008, 9:375 http://www.biomedcentral.com/1471-2164/9/375
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In conclusion, not only simple linear classifiers, but also
more complex non-linear classifiers show a clear benefit
by training them on pooled datasets. Moreover, these
results confirm that the linear nearest mean classifier is
the best candidate for this type of classification problem.
Previously reported classifiers have been using varying
numbers of genes. Signatures that have been derived using
a cross validation setup that is similar to the one used
here, use 52 [20] to around 70 genes [2,3]. We have inves-
tigated the number of genes selected by the DLCV
Scatterplot indicating the classification error relative to the number of datasets that is pooled Figure 6
Scatterplot indicating the classification error relative to the number of datasets that is pooled. A) DLCV error. 
B) Error on the Vijver et al. [3] dataset. C) Number of genes selected by the DLCV protocol. The color corresponds to the 
number of datasets that was used. Poolings with the same number of datasets are sorted based on error/number of genes. 
Labels indicate which combination of datasets was used.
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Correlation between the number of datasets pooled and DLCV error: Pearson=−0.26 p=3.95e−002
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Correlation between the number of datasets pooled and validation error: Pearson=−0.35 p=4.97e−003
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method, for each of our pooled datasets, see Figure 6C.
The classifiers trained on a single dataset use around 50
genes, whereas pooled datasets select progressively more
genes. Especially the classifiers from five or six datasets
select more than 100 genes. These results indicate a posi-
tive trend in the number of datasets pooled and the
number of genes selected in the signatures (Pearson corre-
lation of 0.38 with p = 1.9e - 3).
In summary, the effects observed when pooling artificial
datasets are also observed when pooling breast cancer
datasets. This implies that datasets should be analyzed
jointly rather than in isolation.
Enrichment of the signatures
Functional enrichment of prognostic signatures has
unveiled a multitude of pathways that are associated with
tumor progression. We set out to inspect the effect of
pooling datasets on the enrichment. We used a collection
of 1860 genes sets consisting of at least five annotated
genes (see Methods section). For each pooled combina-
tion, we used the hypergeometric test to assess the signifi-
cance of the overlap, followed by Bonferroni correction
(see Methods section).
The most highly enriched categories were proliferation
associated, which are well-known to be associated with
tumorigenesis. Figure 7 shows the enrichment for three of
the gene sets. Figure 8 depicts a complete heatmap of
enrichments.
As seen in Figure 7A, the mitosis GO category
(GO:0007067: mitosis) shows a significant enrichment
for practically every pooled combination of datasets. This
is an example of a very strong signal, which gets even
stronger when pooling datasets. Another proliferation
related category (Figure 7B), the cell cycle pathway (KEGG
– hsa04110 – Cell cycle) becomes significantly enriched
when roughly three or more datasets are combined. Thus
it's association is weaker than the mitosis gene set, but gets
detected when pooling a few datasets.
Lastly, a gene set associated to microtubule activity
(GO:0003777: microtubule motor activity) is non-signif-
icant for the range of pooling one to three datasets (Figure
7C). When combining four or five it is sometimes picked
up, and is definitely picked up when pooling six datasets.
This is a clear example of a relatively weak signal, which
benefits significantly from pooling datasets.
Conversely, we also observe that many gene sets which are
significant in some of the single/pairs of datasets are no
longer significant when pooling (Figure 8). For instance,
glycolysis related pathways are only picked up in the sig-
nature extracted from the Pawitan et al. [23] dataset. This
is evidence that those categories are specific to this dataset,
but represent false positives within the context of the glo-
bal breast cancer population.
Overall, the enrichment analysis provides further proof
that pooling datasets significantly increases the statistical
power to detect weak signals and filter out false positive
associations.
Heterogeneity amongst the breast cancer datasets
Pooling datasets with a high degree of heterogeneity
might have a detrimental effect on subsequent analysis. A
potential way to limit the heterogeneity would be to
restrict the analysis to known clinical subgroups. To test
this, we split each dataset based on ER status, and repeated
the analysis on each of these subgroups. Of course, these
splits reduce the number of samples and intensify small
sample size related problems. For this reason it becomes
impractical to exhaustively explore all possible stratifica-
tions of the dataset. We chose the ER status since it is
known to have a profound effect on disease progression
and gene expression.
On the subgroup of ER positive samples, we observed the
same trends as on the complete datasets. We observed a
synergetic effect for 10 of the 15 of the pooled pairs of
datasets (see Additional file 7). Moreover, the trends
observed on all samples are also significant on the ER pos-
itive subset (see Additional file 8). Enrichment analysis of
these signatures revealed the same set of categories that
were found on the complete set of samples (see Addi-
tional file 9).
Similarly, we also repeated all analyses on the ER negative
subgroup of samples. We observe the same trends as on all
samples or the ER positive group (see Additional file 10
and 11). However, the classification accuracy on this sub-
group is much lower. A potential explanation for this
observation is that this group of samples is inherently
more difficult to classify, or that the small sample size
related problems play a big role (combining all six data-
sets results in 191 samples).
Enrichment analysis of the signatures from the ER nega-
tive group, leads to a very limited set of enriched gene sets
(see Additional file 12). The most highly enriched cate-
gory is 'GO:0006955: immune response'. This confirms
previous reports on the association of this category with
outcome in the ER negative group [27,28]. However, in
the largest dataset (all ER negative samples), not a single
category is enriched. In both of the ER groups, we
observed the same synergetic trends when pooling data-
sets on cross validation, independent validation, and the
number of genes selected. Therefore, heterogeneity
among the datasets due to ER status is only limited.BMC Genomics 2008, 9:375 http://www.biomedcentral.com/1471-2164/9/375
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Overlap amongst signatures
It has been previously observed that existing signatures
have limited overlap in terms of genes. Several potential
explanations have been proposed for these differences:
1. Heterogeneity in expression due to different platform
technologies and references;
2. Differences in supervised protocols with which signa-
tures are extracted;
Enrichment of three gene sets relative to the number of datasets which is pooled Figure 7
Enrichment of three gene sets relative to the number of datasets which is pooled. A) GO:0007067: mitosis B) 
KEGG – hsa04110 – Cell cycle C) GO:0003777: microtubule motor activity. Scatterplots indicate the minus log10 of the Bon-
ferroni corrected p-values. The red line indicates the level at which 0.01 is reached.
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Correlation between the enrichment of GO:0007067: mitosis and the number of datasets: Pearson=0.54 p=4.03e−006
1 2 3 4 5 6
−5
0
5
10
15
20
D
M
n
P
L
C
M
l
D
 
M
n
M
n
 
P
M
n
 
L
D
 
C
M
n
 
C
P
 
C
L
 
C
M
n
 
M
l
D
 
P
M
l
 
P
M
l
 
C
M
l
 
L
P
 
L
D
 
M
l
D
 
L
D
 
M
n
 
P
M
n
 
P
 
L
D
 
M
n
 
C
M
n
 
M
l
 
C
M
n
 
P
 
C
M
n
 
L
 
C
D
 
P
 
C
M
l
 
L
 
C
D
 
L
 
C
D
 
M
n
 
L
M
n
 
M
l
 
L
P
 
L
 
C
M
n
 
M
l
 
P
M
l
 
P
 
L
M
l
 
P
 
C
D
 
M
n
 
M
l
D
 
P
 
L
D
 
M
l
 
C
D
 
M
l
 
L
D
 
M
l
 
P
D
 
M
n
 
P
 
C
D
 
M
n
 
L
 
C
M
n
 
P
 
L
 
C
M
n
 
M
l
 
L
 
C
M
n
 
M
l
 
P
 
L
D
 
M
n
 
M
l
 
L
M
l
 
P
 
L
 
C
M
n
 
M
l
 
P
 
C
D
 
M
n
 
M
l
 
C
D
 
M
n
 
P
 
L
D
 
M
n
 
M
l
 
P
D
 
M
l
 
P
 
L
D
 
P
 
L
 
C
D
 
M
l
 
L
 
C
D
 
M
l
 
P
 
C
D
 
M
n
 
P
 
L
 
C
D
 
M
n
 
M
l
 
L
 
C
M
n
 
M
l
 
P
 
L
 
C
D
 
M
n
 
M
l
 
P
 
C
D
 
M
n
 
M
l
 
P
 
L
D
 
M
l
 
P
 
L
 
C
D
 
M
n
 
M
l
 
P
 
L
 
C
B
Number of datasets that are pooled
−
l
o
g
1
0
(
B
o
n
f
e
r
r
o
n
i
 
c
o
r
r
e
c
t
e
d
 
P
)
Correlation between the enrichment of KEGG − hsa04110 − Cell cycle and the number of datasets: Pearson=0.54 p=4.39e−006
1 2 3 4 5 6
−5
0
5
10
15
20
D
M
n
P
C
M
l
L
D
 
M
n
M
n
 
P
M
n
 
L
D
 
C
M
n
 
C
P
 
C
M
l
 
C
D
 
P
M
n
 
M
l
M
l
 
P
D
 
L
M
l
 
L
D
 
M
l
P
 
L
L
 
C
D
 
M
n
 
P
M
n
 
M
l
 
P
M
n
 
P
 
L
M
n
 
M
l
 
C
M
n
 
P
 
C
M
l
 
P
 
C
D
 
L
 
C
D
 
M
n
 
C
D
 
P
 
C
D
 
M
n
 
L
D
 
M
l
 
P
D
 
M
l
 
C
M
n
 
L
 
C
D
 
P
 
L
M
l
 
P
 
L
P
 
L
 
C
M
l
 
L
 
C
M
n
 
M
l
 
L
D
 
M
n
 
M
l
D
 
M
l
 
L
D
 
M
n
 
M
l
 
C
M
n
 
M
l
 
P
 
C
D
 
M
n
 
L
 
C
D
 
M
n
 
P
 
C
D
 
M
l
 
P
 
C
D
 
M
n
 
P
 
L
M
n
 
P
 
L
 
C
D
 
P
 
L
 
C
M
n
 
M
l
 
P
 
L
D
 
M
l
 
L
 
C
D
 
M
n
 
M
l
 
L
M
l
 
P
 
L
 
C
M
n
 
M
l
 
L
 
C
D
 
M
l
 
P
 
L
D
 
M
n
 
M
l
 
P
D
 
M
n
 
P
 
L
 
C
M
n
 
M
l
 
P
 
L
 
C
D
 
M
l
 
P
 
L
 
C
D
 
M
n
 
M
l
 
P
 
C
D
 
M
n
 
M
l
 
P
 
L
D
 
M
n
 
M
l
 
L
 
C
D
 
M
n
 
M
l
 
P
 
L
 
C
C
Number of datasets that are pooled
−
l
o
g
1
0
(
B
o
n
f
e
r
r
o
n
i
 
c
o
r
r
e
c
t
e
d
 
P
)
Correlation between the enrichment of GO:0003777: microtubule motor activity and the number of datasets: Pearson=0.65 p=1.04e−008BMC Genomics 2008, 9:375 http://www.biomedcentral.com/1471-2164/9/375
Page 12 of 22
(page number not for citation purposes)
Heatmap of the Bonferroni corrected p-values of the enrichment between each signature and a collection of gene sets Figure 8
Heatmap of the Bonferroni corrected p-values of the enrichment between each signature and a collection of 
gene sets. Only categories with at least 1 significant association are shown.
Signatures from each combination of pooled datasets
Enrichment p−values, Bonferroni corrected per signature, for each gene set at least 1 enrichment p<0.05
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3. Although the genes are not exactly the same, they repre-
sent the same set of pathways;
4. Differences in clinical composition between datasets
(i.e. sample heterogeneity) and
5. Small sample size problems that cause inaccurate signa-
tures.
Here we will critically evaluate whether we observe sup-
port for each of these explanations in the context of the six
breast cancer datasets we studied.
Explanations 1 and 2
In our analysis, we have restricted ourselves to the same
platform for training our classifiers, and use the same
supervised protocol on all datasets. This allowed us to
check whether the first two explanations apply. We evalu-
ated the relative overlap of every combination of two sig-
natures that were extracted from a single dataset, see
Figure 9A. For these 15 comparisons, the majority of genes
are exclusively part of one signature (mean overlap 1.8%).
This clearly indicates that, within the context of the data-
sets studied here, Explanations 1 and 2 are not the likely
causes of the limited overlap between the signatures from
these six datasets.
Histograms indicating the percentage of genes (A-C) and enriched gene sets (D-F) that overlap between two signatures Figure 9
Histograms indicating the percentage of genes (A-C) and enriched gene sets (D-F) that overlap between two 
signatures. A and D) Median histogram and hypergeometric p-value across every pairwise comparison of signatures from sin-
gle datasets. B and E) Median histogram and hypergeometric p-value across every pairwise comparison of signatures from 2 
pooled datasets C and F) Average histogram and hypergeometric p-value across every pairwise comparison of signatures from 
3 pooled datasets. We only considered the comparisons of pooled datasets that do not overlap in terms of samples, e.g. the 
comparison of the signatures from 'Des Loi' and 'Des Paw' is excluded to avoid any bias.
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Explanation 3
Using our functional enrichment analysis we checked
Explanation 3. The enrichment patterns of the signatures
from single datasets are largely disparate (Figure 7). Two
of the six signatures are not enriched for any functional
category. There is only one gene set (GO:0007049: cell
cycle), which is enriched in three signatures, namely those
derived from Desmedt et al. [4], Miller et al. [18], and Loi
et al. [24]. When considering the set of enriched gene sets
that overlap between every pair of signatures (Figure 9D),
we observed a mean overlap of less than 1%. Taken
together, this indicates that there is very little support for
the third explanation in these six datasets.
Explanation 4
Breast cancer is well known to be a complex disease which
manifests itself in a range of subtypes. As a result, differ-
ences in the clinical composition of different datasets
might explain the different signatures. However, when
creating a histogram of signature overlap within the ER
positive/negative subgroups we also found that the major-
ity of genes are only part of one signature. Thus, heteroge-
neity with respect to ER status does not explain the limited
degree of overlap among the signatures from these six
datasets. Of course, it could still be that differences in the
composition with respect to another (unknown) clinical
parameter partly explain the lack of overlap.
Explanation 5
Signatures that are derived from pooled datasets have
been derived using more samples, thereby easing small
sample size related difficulties. Therefore, we inspected
the relative overlap between signatures derived from one,
two and three datasets. To avoid any bias, we only con-
sider pairs of pooled datasets that do not overlap in terms
of samples. The histogram and p-values shown in Figure
9A–C represent the mean over all these combinations.
The overlap becomes progressively larger for signatures
that are extracted from larger datasets (single dataset:
1.8%, two pooled datasets: 8.1%, three pooled datasets:
13.1%). At the same time this overlap becomes more sig-
nificant (single dataset: -log10(p) = 2.1, two pooled data-
sets: -log10(p) = 13.6, three pooled datasets: -log10(p) =
23.2). The same trends were observed on the artificial
data, and the ER positive subgroup (results not shown).
Next, we repeated this analysis by looking for overlap in
terms of enriched gene sets (Figure 9D–F). Similarly, sig-
natures derived from the pooled datasets show a higher
degree of enriched gene sets that overlap. The distinguish-
ing property of these signatures is the fact that they were
derived from a larger dataset, i.e. more samples. Thus, we
conclude that Explanation 5 is the most relevant explana-
tion for the low degree of overlap in genes from signatures
derived from these six datasets.
Consensus signature across six datasets
The signature from the six pooled datasets will be substan-
tially different from those derived from each individual
dataset. To gain insight into the difference, we created a
chart indicating the rank position of all 127 genes selected
in the classifier trained on all six datasets, along with rank
positions from these genes in the rankings obtained from
the individual datasets (Figure 10). Additional file 13 con-
tains detailed information on the 127 genes, and the cen-
troids of the classifier. Most of the 127 signature genes,
had a much lower rank (larger rank number) in the indi-
vidual signatures, implying that they're not part of those
signatures. The difference in ranking of the 127 genes is
especially large compared to the signature derived from
the Minn et al. [22] and Chin et al. [25] data. This implies
that those rankings are dominated by genes which are not
generally relevant for breast cancer.
We compared our signature to signatures derived from
different breast cancer datasets. We compared to the 70-
gene signature from Wang et al. [2], 76-gene signature
from Vijver et al. [3], 70-gene signature from Naderi et al.
[19], and the 52-gene signature from Teschendorff et al.
[20]. The latter of which was derived from the first three
datasets. None of these three datasets were employed to
derive the 127 gene signature. The overlap between the
127 genes and the Teschendorff signature is more signifi-
cant (p = 2.3e - 18) than with Naderi (p = 1.2e - 11), Vijver
(p = 7.4e - 7) or Wang (p = 4.7e - 1). This provides addi-
tional evidence that the limited signature overlap is most
likely caused by small sample size difficulties.
The set of genes in the signature from all six datasets con-
tains many well known and described genes. For instance,
it confirms the significance of HMMR (Rank 127, Figure
10) which was only recently associated with breast cancer
[29]. This gene was not picked up in any of the individual
signatures. In the same study, Pujana et al. [29] derived a
set of 164 genes that are associated with BRCA1, BRCA2,
ATM, and CHEK2. This set of 164 genes is significantly
overrepresented in the 127 signature genes (p = 2.4e - 9).
Biological relevance of the consensus signature
Cell cycle and Mitosis pathways are the common back-
ground of most prognostic gene expression classifiers. Not
surprisingly, many of the 127 genes have been previously
described as markers of proliferation and poor prognosis
in different types of cancer. These include: BUB1B, BUB1,
MAD2L1, C16orf61 (DC13), CCT5, EIF4EBP1, MELK,
MYBL2, CCNA2, CCNB1 and CCNB2. More specifically,
EIF4EBP1 (4E-binding protein 1, 4E-BP1) is a EIF4E-bind-
ing protein that plays a critical role in the control of pro-
tein synthesis, survival, and cell growth. Rojo et al. [30]
showed that 4EBP1 is activated in a high percentage of
breast tumors, and is associated with higher malignantBMC Genomics 2008, 9:375 http://www.biomedcentral.com/1471-2164/9/375
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Chart listing the 127 genes selected in the classifier trained on all six datasets Figure 10
Chart listing the 127 genes selected in the classifier trained on all six datasets. For each gene, we list the rank, Ent-
rez id, and Gene symbol. Green cell shading indicates the genes that are part of the signature from the six pooled datasets, 
which are not part of any of the signatures from the single datasets. Yellow cell shading indicates the seven microtubule associ-
ated genes. The succeeding columns indicate the rank position of a particular gene in each of the six separate rankings. An 
orange cell shading indicates the genes that were part of the individual signatures. The purple cell shading indicates the overlap 
to a group of existing breast cancer signatures (Wang et al. [2], Vijver et al. [3], Naderi et al. [19], Teschendorff et al. [20]), and 
a group of breast cancer associated genes (Pujana et al. [29]). P-values indicating the significance of the overlap (hypergeometric 
test) of these signatures is given at the bottom of the columns.
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2471 11452 378 75 41 6982
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382 494 1589 384 1644 771
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grade, tumor size, and local recurrence regardless of
HER2/neu status (Armengol et al. [31]). Lin et al. [32]
showed that MELK (maternal embryonic leucine zipper
kinase), is overexpressed in both breast cancer specimens
and cancer cell lines, and that its kinase activity possibly
plays a significant role in breast cancer cell proliferation.
They show that down-regulation of MELK by treatment
with siRNA significantly suppressed the cell growth of
breast cancer, indicating its crucial role in the prolifera-
tion of breast cancer.
C16orf61 (DC13) and CCT5 are examples of genes asso-
ciated with therapy resistance. More specifically,
C16orf61 (DC13) was previously found to be involved in
multidrug resistance in breast cancer [33], and mRNA lev-
els of CCT5 were significantly associated with resistance to
docetaxel [34].
Cellular movement and cytokinesis pathways are signifi-
cantly over-represented in our prognostic signature
mainly through genes (KIF23, KIFC1, KIF14, KIF20A,
KIF2C, KIF13B, KIF4A, PRC1, TUBB3, TPX2, CENP-A)
linked to the microtubule motor activity (GO:0003777)
and the microtubule-based movement (GO:0007018)
GO categories. It is of major interest that these GO catego-
ries are non-significant for the range of pooling one to
three datasets and are only picked up when pooling more
datasets.
The genes that are associated with the microtubule catego-
ries are all part of the kinesin family. This family is com-
posed of more than 40 genes involved in spindle
assembly and function, chromosome segregation, mitotic
checkpoint control and cytokinesis. They are motor pro-
teins that generate movement along microtubules. KIF14
is a prognostic factor in breast and lung cancer (Corson et
al. [35,36]). KIF20A is over-expressed in pancreatic ductal
adenocarcinoma (PDAC) and siRNA knockdown of
KIF20A expression in PDAC cell lines attenuated growth
of those cells (Taniuchi et al. [37]). KIF2C is also known
to be over-expressed in breast cancer cells. Treatment of
breast cancer cells (T47D and HBC5) by siRNA against
KIF2C suppressed KIF2C expression and inhibited the
growth of the breast cancer cell lines (Shimo et al. [38]).
Immunoprecipitation assay showed an interaction
between PRC1 and KIF2C in breast cancer cells (Shimo et
al.  [38]). KIF4a is overexpressed in cervical cancer
(Narayan et al. [39]). Treatment of lung cancer cells with
siRNA for KIF4A suppressed the growth of these cells and
induction of exogenous expression conferred cellular
invasive activity on mammalians cells (Taniwaki et al.
[40]). TUBB3 over-expression is a marker of poor prog-
nostic in pancreatic, non-small cell lung carcinoma and
ovarian cancer (Ferrandina et al. [41], Seve et al. [42,43],
Lee et al. [44]) and is a potential marker of resistance to
treatment by paclitaxel or vinorelbine-based chemother-
apy. Kinesin related genes are currently vigorously pur-
sued as therapeutic targets. Taxanes and Vinca alkaloids
are major drugs in the clinical routine and are designed to
bind and inhibit the motor function of the microtubules.
The high frequency of side-effect of these drugs is due to
the simultaneous alteration of microtubule cell-resting
and differentiation function.
Drug companies are now putting an effort into the devel-
opment of new molecules specifically targeting the
kinesin family. Four other genes also present in the signa-
ture, TENC1, SEMA3G, CXCL12, and CX3CR1 also play a
role in regulating cell motility and migration independ-
ently of the microtubule pathways (Chen et al. [45], Yu et
al [46], Lopez-Bendito et al. [47], Lauro et al. [48]).
Taken together, this shows that many of the genes in the
consensus signature have been characterized within a
breast cancer con- text, and some have even been consid-
ered as drug targets. Nevertheless, not all of them have
been covered, opening up possibilities for follow-up anal-
ysis. The fact that these genes have been derived from a
compendium of six pooled datasets boosts confidence in
their relevance within a clinical context.
Conclusion
In our analysis we aimed to extract a robust classifier from
multiple datasets. We explored the possibility of pooling
datasets, which should alleviate small sample size related
problems, and increase robustness. For a single dataset,
we revisited the resampling strategy [5,13] which has been
employed as a 'gold standard' for evaluating gene sets and
has been applied to extract robust signatures, e.g. Yu et al.
[14]. Our analysis provides proof that the resampling
strategy does not alleviate potential problems due to sam-
pling biases. Instead, by only taking the top N genes in
every resampling into account, the obtained feature rank-
ing is inferior to the ranking obtained based on all sam-
ples. Combining the statistics from each of the individual
resamplings (either SNRs or Ranks), provides a ranking
which is equivalent to the ranking based on all samples.
Therefore, we propose to use the ranking over all samples
in order to train a final classifier. 
Concurrent analysis of multiple datasets is an established
way to increase statistical power, and thereby robustness.
Pooling the datasets prior to any analysis would enable
the largest gain in statistical power. We presented an
example of pooling artificial datasets, which unveiled a
significant negative correlation between the number of
datasets which is pooled, and the DLCV error/validation
error. We also observed a significant positive correlation
between the degree of pooling and the number of genesBMC Genomics 2008, 9:375 http://www.biomedcentral.com/1471-2164/9/375
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which is selected. Thus, on the artificial data there is a
clear synergetic effect associated with pooling of datasets.
Similarly, pooling breast cancer datasets represents a way
to improve classification performance, since the pooled
datasets will provide a better resemblance to the true
underlying breast cancer population. For instance, breast
cancer subtypes that are not present in one dataset might
be present in another. A classifier trained on a pooled
dataset was hypothesized to be more robust when applied
to unseen, independent data. To test this hypothesis, we
used a collection of six independent datasets, all meas-
ured on the same platform. Indeed, we observed a lower
classification error for classifiers trained on pooled data-
sets. This significant trend is supported by a validation on
a seventh independent dataset. The trends observed for
pooling datasets strongly confirm the belief that there is a
synergetic effect between pooling datasets and classifica-
tion performance. Recently, another group [21] has come
to a similar conclusion, albeit using only three datasets for
training, and one for testing. A shortcoming in their anal-
ysis is that they do not switch the roles of which datasets
are used for training and testing. Moreover, they mention
the issue of small overlap among signatures, but do not
provide any clear answers to that issue. Pooling in itself
might lead to unwanted effects (i.e. Simpson's Paradox,
[49]). Our results do not rule out the existence of detri-
mental effects due to pooling heterogeneous datasets, but
imply that the synergetic effect of pooling is stronger than
the detrimental effect of heterogeneity.
Signatures that have been extracted from independent
cohorts of patients share only a limited number of genes.
A variety of explanations have been proposed, only some
of which have been thoroughly tested. We have checked
whether there is any support for five of these explanations.
On a collection of six breast cancer datasets, which were
all measured on the same array, we applied the same
supervised protocol. This lead to signatures that still lack
overlap in terms of genes contained in the signatures. Sim-
ilarly, our results point out that the overlap in terms of
enriched pathways is just as limited, and reducing hetero-
geneity by stratifying based on ER status does not resolve
the issue either. Of course, ER status might not be the only
important source of heterogeneity. Therefore, we cannot
completely rule out the effect of data heterogeneity on sig-
nature overlap. We believe that the limited signature over-
lap is most likely due to small sample size problems
(Explanation 5). More specifically, that the variability
between classifiers stems from the fact that the individual
datasets are too small to capture the important sources of
variation in the data. Moreover, pooling datasets might
average-out adverse effects from heterogeneity that is only
present in a subset of the samples/datasets. Explanation 5
is supported by a much larger overlap between signatures
from pooled datasets than between signatures derived
from single datasets. Nevertheless, we would like to point
out that these conclusions might be specific to the six
breast cancer datasets analyzed here and the specific tech-
niques we employed to perform these analyses. That is,
this conclusion may not extrapolate to different datasets/
other tumor types.
Further evidence for the synergetic effect of pooling data-
sets comes from the functional enrichment analysis. We
observed both low signal associations that become
stronger, as well as categories that we can label as false
positive associations since they're only found in one data-
set and disappear when the complete set is analyzed.
Moreover, we pick up relevant breast cancer associated
genes in the signature derived from six pooled dataset,
that are not picked up in any of the signatures from the
separate datasets. Many of the genes in the signature have
been previously characterized as drug targets and since
our analysis is based on a large compendium it boosts our
confidence in their potential relevance for clinical prac-
tice.
Overall, we hypothesize that the 127 gene signature that
was derived from the six pooled datasets is one of the
most robust signatures currently available. Our results
indicate that new breast cancer datasets should not be
analyzed in isolation, but should be analyzed in the con-
text of the available compendium of breast cancer sam-
ples
Methods
Resampling procedure
The resampling strategy has been proposed for the deriva-
tion of robust signatures [5,13]. Briefly, the strategy works
as follows. First, a subset of s% of the samples is selected,
stratified relative to the outcome variable of interest. Sec-
ond, for this subset all available genes G are ranked based
on an appropriate selection statistic (e.g. the signal to
noise ratio). Third, for each of R resamplings the top N
genes are stored. The frequency of a gene being among the
top N genes determines its final rank.
All genes with a non-zero frequency of appearing in the
top N genes at least once can be considered part of the
resulting robust signature [13]. However, when assessing
a large number of resamplings, one would expect a fair
number of genes to achieve a non-zero frequency by
chance. To remove these genes, we propose to apply a
threshold. Under the null hypothesis that there is no
information in the dataset, we assume that each of the
resamplings is a Bernouilli trial (with  ). Under the
null hypothesis, how often a gene appears in the top N
p N
G =BMC Genomics 2008, 9:375 http://www.biomedcentral.com/1471-2164/9/375
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across the R resamplings follows a Binomial distribution,
with an expected value (E) of  . Consequently,
when assessing the frequency of occurrence in the top N,
we divide by R again, leading to the following threshold t:
In our analysis, we used the resampling strategy in con-
junction with the SNR (signal to noise ratio) as a ranking
criterion. Assuming a dataset A, the absolute SNR is
defined as:
where SNR(i) represents the SNR of gene i, μ(Ai1) repre-
sents the mean of gene i for all samples in the class 1, and
σ(Ai1) represents the standard deviation of gene i for all
samples in the class 1.
Double loop cross validation
Wessels et al. [26] described a generally applicable frame-
work for building diagnostic classifiers from high
throughput data. We adopted this methodology com-
bined with forward filtering as feature selector, the signal
to noise ratio as criterion to evaluate the individual genes,
and a nearest mean classifier (cosine correlation as dis-
tance measure). The training and validation procedure
was performed employing 20 repeats of 5 folds cross vali-
dation in the outer (validation) loop, and 10 fold cross
validation in the inner loop. Learning curves were con-
structed for up to 200 genes. At all points data splits were
stratified with respect to the class prior probabilities.
The double loop cross validation method can be
described in a few steps:
1. For each repeat, the data is split (stratified) into five
parts (different splits for each repeat).
2. For each fold, four parts are used for the inner loop
(training set), the fifth is used in the outer loop for valida-
tion (validation set).
3. On the training set data, a 10-fold cross validation is
performed to estimate the optimal number of genes n.
4. Next, a classifier is trained on the complete training set,
using the top n genes.
5. Finally, the performance of that classifier is assessed on
the validation set.
6. After all repeats are completed, a final classifier is cre-
ated by ranking the genes using all samples. The average
number of n that were obtained are used to train the clas-
sifier. This classifier is then applied on an external valida-
tion set.
Typically, datasets are unbalanced with respect to the class
priors. Moreover, the class priors will be different for dif-
ferent datasets. Hence, directly comparing overall error
rates (fraction of wrong assignments), is not an appropri-
ate comparative measure. Therefore, classification errors
were calculated by using the average false positive false
negative ratio (which takes the class priors into account),
which is defined as:
where eFPFN represents the average false positive false neg-
ative ratio error, TP the number of true positives, and TN
the number of true negatives. This ratio is equivalent to 1-
.5(Sensitivity + Specificity). In each iteration in the inner
loop, n is defined as the number of genes at which the
eFPFN is minimal.
When we refer to the DLCV error, this is the validation
error assessed in the outer loop of the protocol. In addi-
tion to the linear nearest mean classifier, we also per-
formed the experiments using more complex, non-linear
classifiers. To this end, we used a k-nearest neighbor clas-
sifier (K-NN) as well as a Support Vector Machine with a
Radial Basis Function as kernel (SVM with RBF kernel).
The K-NN classifier was run using K = 3 and the cosine
correlation as distance measure. For the SVM we used the
following parameters: C = 5 and λ = 2 (RBF kernel width).
These two classifiers were used in conjunction with the
same double loop cross validation protocol.
Artificial dataset
An artificial dataset was used to be able to compare the
ranking obtained by different strategies to a known
ground truth. To this end, we generate a dataset which is
comparable to microarray datasets in terms of dataset size.
We constructed an artificial dataset with M samples and G
genes. The data for each feature was sampled from the fol-
lowing two class conditional density functions:
P(X|ω1) = N(μ(j), 1) (4)
P(X|ω2) = N(-μ(j), 1) (5)
where
E RN
G =
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N
G
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The data that is generated using this model is more ideal
than real-life microarray data, since it does not include
any covariance terms. Artificial datasets were generated
with the following setting of the parameters:
M = 100 to 1000 (7)
G = 5000 (8)
J = {500, 2500, 5000} (9)
μ0 = .1 (10)
P(ω1) = .5 (11)
P(ω2) = .5 (12)
Breast cancer datasets
The data from Veer et al. [1] was downloaded from the
repository mentioned in the paper. Preprocessing was
done as follows, the 24481 probes were pruned to 4919
by using only probes with at least a twofold change and p
< 0.01 for three or more arrays [1].
We used a collection of six available datasets containing
microarray data of breast cancer samples. These datasets
were all measured on Human Genome HG U133A
Affymetrix arrays and normalized using the same proto-
col. The datasets were downloaded from NCBI's Gene
Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/) with the following identifi-
ers; GSE6532 [24], GSE3494 [18], GSE1456 [23],
GSE7390 [4] and GSE5327 [22]. The Chin et al. [25] data
set was downloaded from ArrayExpress (http://
www.ebi.ac.uk/, identifier E-TABM-158).
To ensure comparability between the different datasets,
they were all subjected to the same pre-processing proce-
dure. Microarray quality-control assessment was carried
out using the R AffyPLM package available from the Bio-
conductor web site (http://www.bioconductor.org, [50]).
We applied the Relative Log Expression (RLE) test and the
Normalized Unscaled Standard Errors (NUSE) test. Chip
pseudo-images were produced to assess artifacts on arrays
that didn't pass the preceding quality control tests.
Selected arrays were normalized according to a three step
procedure using the RMA expression measure algorithm
(http://www.bioconductor.org, [51]): RMA background
correction convolution, median centering of each gene
across arrays separately for each data set and quantile nor-
malization of all arrays.
For each sample, the ER status was determined by the
expression profile [52]. This ensures a consistent assign-
ment of the ER status across all samples, and rules out any
inconsistencies in the assignments by pathologists. In
addition, for part of the samples the IHC ER status was
unavailable (see Additional file 14). All samples were
ranked based on the expression level of the ER probe
(probe 205225_at), after which we constructed an ROC
curve using the IHC (Immuno-histo chemistry) assign-
ment as true label. We then selected the threshold which
resulted in the smallest error with regard to the true label
(ERneg when 205225_at ≤ -1.84, ERpos when 205225_at
> -1.84).
For the datasets from Desmedt, Miller, Pawitan, and Loi,
there is an overlap in terms of samples. Part of these sam-
ples have been re-used, either with the same data (overlap
Loi/Miller), or after a new hybridization (overlap Des-
medt/Miller). We excluded all overlapping samples from
the Desmedt and Loi datasets. This way, we ensured inde-
pendence of the datasets, and avoid any bias.
We used the dataset from Vijver et al. [3] as an independ-
ent validation. This dataset was measured on the Agilent
platform.
To validate the classifier trained on the six Affymetrix
datasets on the Agilent dataset, we had to map the two
probesets. We did this by mapping the probes from both
platforms to the set of Entrez ids (11751) present on both.
For the HG U133A array, only probes with an '_at', '_s_at',
and '_x_at' extension were used (and prioritized in this
order). When multiple probes match the same Entrez id
(and had the same extension), the one with the highest
variance was used.
Poor and good subgroups were defined as follows: Poor
refers to samples with an event within five years, whereas
Good refers to samples with event free survival and at least
five years follow up.
Table 1 provides an overview of the datasets that were
used.
Functional enrichment analysis
For all signatures, we evaluated whether specific gene sets
(i.e. functional groups), are overrepresented. We gathered
a collection of 5480 gene sets from four databases: Gene
Ontology (http://www.ncbi.nlm.nih.gov/, Function and
Process trees, 4745 gene sets), KEGG (http://
www.genome.ad.jp,187genesets), Reactome (http://
www.reactome.org, 26 gene sets) and the MSDB (http://
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www.broad.mit.edu/gsea/, C2, 522 gene sets). For the
enrichment analysis we only used gene sets with at least
five annotated Entrez IDs that are also present on the
array, resulting in 1860 gene sets. We used the hypergeo-
metric test to test the significance of the overlap between
each signature and gene set. Multiple testing correction
was taken into account by applying a Bonferroni correc-
tion (per signature).
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used. Labels indicate which combination of datasets was used.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-375-S2.pdf]
Additional file 3
Scatterplot indicating the classification error relative to the number of 
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combination of datasets was used.
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